{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:12:46Z","timestamp":1769508766438,"version":"3.49.0"},"reference-count":20,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"consolidated funds for clinical research of the Hematology-Oncology department at the CHU de Qu\u00e9bec"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these regimens is available to provide objective guidance in clinical decision making. The primary objective of this study was to compare the cumulative dose of paclitaxel delivered using 80 mg\/m2\/week, administered using either a 3 weeks out of 4 (WP3) or a 4 weeks out of 4 (WP4) regimen. The secondary objective was to evaluate the clinical outcomes associated with both regimens, including efficacy and toxicity parameters. Our retrospective cohort comprised 149 patients harboring platinum-resistant ovarian cancer treated at the CHU de Qu\u00e9bec from January 2012 to January 2023. WP3 and WP4 reached a similar cumulative dose (1353.7 vs. 1404.2 mg\/m2; p = 0.29). No significant differences in the clinical outcomes were observed. The frequency of dose reduction was significantly higher for WP4 than WP3 (44.7% vs. 4.9%; p &lt; 0.01), mainly due to treatment intolerance from toxicity (34.0% vs. 3.9%; p &lt; 0.01). Our data suggest that a WP3 regimen delivers a similar cumulative dose to WP4, hence offering a better tolerability profile without compromising efficacy.<\/jats:p>","DOI":"10.3390\/curroncol31080345","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T05:47:11Z","timestamp":1723700831000},"page":"4624-4631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7342-0311","authenticated-orcid":false,"given":"Laurence","family":"Morin","sequence":"first","affiliation":[{"name":"Medical Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6718-6160","authenticated-orcid":false,"given":"Louis-Philippe","family":"Grenier","sequence":"additional","affiliation":[{"name":"Medical Oncology Pharmacy Department, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Foucault","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Unit\u00e9 de Formation et de Recherche en Sant\u00e9 de Rouen, 76183 Normandie, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"L\u00e9vesque","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Fabi","sequence":"additional","affiliation":[{"name":"Radio-Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve-Lyne","family":"Langlais","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Sebastianelli","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Lavoie","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Lalancette","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-7913","authenticated-orcid":false,"given":"Marie","family":"Plante","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahukpe","family":"Singbo","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1E 6W2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 5B3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Statistics Advisory Committee (2023). Canadian Cancer Statistics 2023, Canadian Cancer Society."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"National Comprehensive Cancer Network (2024, July 01). NCCN Clinical Practice Guidelines in Oncology\u2014Ovarian Cancer. Available online: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/ovarian-patient.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","article-title":"Chemoresistance in ovarian cancer: Exploiting cancer stem cell metabolism","volume":"29","author":"Li","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clon.2014.10.001","article-title":"Dose-dense Paclitaxel in Advanced Ovarian Cancer","volume":"27","author":"Kumar","year":"2015","journal-title":"Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","article-title":"Weekly paclitaxel in the treatment of recurrent ovarian cancer","volume":"7","author":"Baird","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","first-page":"79","article-title":"Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma","volume":"26","author":"Dunder","year":"2005","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_12","first-page":"383","article-title":"A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients","volume":"23","author":"Kaern","year":"2002","journal-title":"Eur. J. Gynaec. Oncol.-IssN"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2003.12.002","article-title":"The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer","volume":"92","author":"Kita","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum\/Paclitaxel-Refractory Ovarian Cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cazzaniga, M.E., Cordani, N., Capici, S., Cogliati, V., Riva, F., and Cerrito, M.G. (2021). Metronomic Chemotherapy. Cancers, 13.","DOI":"10.3390\/cancers13092236"},{"key":"ref_17","first-page":"1833","article-title":"Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer","volume":"22","author":"Takano","year":"2002","journal-title":"Anticancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-024-01034-6","article-title":"Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: A real-world analysis","volume":"14","author":"Hoff","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:36:49Z","timestamp":1760110609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["curroncol31080345"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31080345","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}